Forian Inc., a provider of data science-driven information and analytics solutions, reported financial results for the fourth quarter and full year ended December 31, 2025. The company demonstrated substantial revenue growth while managing costs and strategic investments, though profitability metrics showed mixed results. Forian's performance reflects its expanding footprint in the life sciences and healthcare analytics sectors, even as it faces potential ownership changes through a proposed acquisition by its leadership.
For the full year 2025, Forian achieved revenue of $30.3 million, representing a 50% increase from $20.2 million in 2024. This growth was driven by key contract renewals that offset customer churn and data supply challenges. However, the company reported a net loss of $2.9 million for the year, an improvement from the $3.8 million loss in 2024. Adjusted EBITDA, a non-GAAP measure, increased 72% to $840,408 from $489,134 in the prior year.
The fourth quarter presented a more complex picture. Revenue grew 37% to $8.0 million from $5.8 million in the same period last year, but the company swung to a net loss of $1.8 million from net income of $0.2 million in Q4 2024. Adjusted EBITDA was negative $170,531 compared to positive $120,599 in the prior year quarter. Despite these quarterly challenges, Forian ended the year with strong liquidity, holding $31.6 million in cash, cash equivalents and marketable securities.
Chief Executive Officer Max Wygod emphasized the company's balanced approach. "We grew our business, expanded into new markets, and made targeted investments in our data platform and product development while maintaining a cost-conscious approach that preserved the strength of our balance sheet," Wygod stated in the earnings release. The company highlighted several operational achievements, including expanding its pharmaceutical and biotech customer base, strengthening data partnerships, and onboarding new clinical data feeds to address upstream data supply challenges.
A significant development overshadowing the financial results is the potential acquisition of Forian by a consortium led by CEO Max Wygod and Executive Chair. On August 25, 2025, the consortium submitted a non-binding proposal to acquire all outstanding shares not currently owned by the group. A Special Committee formed to evaluate the proposal remains in discussions with the consortium, though Forian cautioned that "there can be no assurance that any transaction will result from these discussions." The company stated it does not intend to comment further unless a definitive agreement is reached or disclosure becomes necessary.
The financial results and potential acquisition come as Forian continues to expand its data analytics offerings across life sciences, healthcare and, through its recent acquisition of Kyber Data Science, financial services. The company's ability to grow revenue while managing costs demonstrates the increasing demand for healthcare data analytics solutions, particularly as pharmaceutical and biotech companies seek more sophisticated tools to optimize operations and measure performance. For more information about the company's financial results, investors can visit https://www.forian.com/investors.
Forian's performance highlights several important trends in the healthcare analytics industry. The 50% revenue growth indicates strong market demand for data-driven solutions that can help life sciences companies navigate complex regulatory environments and optimize clinical and financial performance. The company's expansion into pharmaceutical and biotech markets suggests these sectors are increasingly adopting advanced analytics to drive decision-making. However, the quarterly profitability challenges and ongoing net losses underscore the competitive nature of the industry and the significant investments required to maintain technological leadership.
The potential acquisition by company leadership adds another layer of complexity to Forian's story. Such management-led buyouts often signal confidence in the company's future prospects but can also create uncertainty for public shareholders. The outcome of these discussions could significantly impact Forian's strategic direction and capital structure moving forward. As healthcare data continues to grow in volume and importance, companies like Forian that can effectively manage, analyze and commercialize this information are positioned to play increasingly critical roles in the healthcare ecosystem.
